Cargando…

DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU)

OBJECTIVES: The immune checkpoint molecule PD-L1 (CD274) is a crucial regulator of the tumor immune response. Its expression has been reported in the therapeutic context in Head and Neck Squamous Cell Carcinoma (HNSCC), but it remains unclear how therapeutically approved molecules regulate PD-L1 exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lailler, Claire, Lamuraglia, Michele, Racine, Floriane, Louandre, Christophe, Godin, Corinne, Chauffert, Bruno, Galmiche, Antoine, Saidak, Zuzana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111315/ https://www.ncbi.nlm.nih.gov/pubmed/33951601 http://dx.doi.org/10.1016/j.tranon.2021.101110

Ejemplares similares

The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers
por: Racine, Floriane, et al.
Publicado: (2023)

ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma
por: Lailler, Claire, et al.
Publicado: (2019)

Contribution of Genomics to the Surgical Management and Study of Oral Cancer
por: Saidak, Zuzana, et al.
Publicado: (2021)

Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib
por: Houessinon, Aline, et al.
Publicado: (2016)

A pan-cancer study of the transcriptional regulation of uricogenesis in human tumours: pathological and pharmacological correlates
por: Saidak, Zuzana, et al.
Publicado: (2018)

Molecular Landscape of the Coagulome of Oral Squamous Cell Carcinoma
por: Lottin, Marine, et al.
Publicado: (2022)

Fluorouracil (5-FU)-induced Cardiomyopathy
por: Thalambedu, Nishanth, et al.
Publicado: (2019)

Protein biosynthesis, a target of sorafenib, interferes with the unfolded protein response (UPR) and ferroptosis in hepatocellular carcinoma cells
por: Sauzay, Chloé, et al.
Publicado: (2018)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
por: De Angelis, Paula M, et al.
Publicado: (2006)

Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals
por: Ahmad, Maqsood, et al.
Publicado: (2012)

A unique presentation of 5-fluorouracil (5-FU) induced cerebral encephalopathy
por: Naik, Shailendra S, et al.
Publicado: (2020)

Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells
por: Kim, Eun-Ji, et al.
Publicado: (2018)

Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies
por: Donnadieu, Jérôme, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.
por: Goldberg, J. A., et al.
Publicado: (1988)

Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil
por: Han, Jung Ho, et al.
Publicado: (2021)

Targeting coagulation to unlock antitumor immunity?
por: Galmiche, Antoine, et al.
Publicado: (2022)

Transcriptomic and network pharmacology approaches revealed possible mechanisms underlying the 5-fluorouracil (5-FU)-sensitizing effect of Xuan-Fu-Hua decoction treatment on liver cancer cells
por: Luo, Wen-Zhao, et al.
Publicado: (2022)

Therapeutic Perspectives for the Perioperative Period in Oral Squamous Cell Carcinoma (OSCC)
por: Galmiche, Antoine, et al.
Publicado: (2022)

Impact and Relevance of the Unfolded Protein Response in HNSCC
por: Pluquet, Olivier, et al.
Publicado: (2019)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma.
por: Zaniboni, A., et al.
Publicado: (1988)

Efficacy of Fractional Carbon Dioxide Laser (FCO(2)) with Intralesional 5-Fluorouracil (5-FU) in the Treatment of Keloids
por: Alhamzawi, Nabeel Kadhim
Publicado: (2021)

Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells
por: Qayum, Arem, et al.
Publicado: (2022)

Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines
por: Suetsugu, Tomonari, et al.
Publicado: (2021)

Evaluation of Proton MR Spectroscopy for the Study of the Tongue Tissue in Healthy Subjects and Patients With Tongue Squamous Cell Carcinoma: Preliminary Findings
por: Boussida, Salem, et al.
Publicado: (2022)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
por: Zafar, Amna, et al.
Publicado: (2022)

Eukaryotic translation initiation factor 3 subunit G (EIF3G) resensitized HCT116/5-Fu to 5-fluorouracil (5-Fu) via inhibition of MRP and MDR1
por: Yang, Chenggang, et al.
Publicado: (2018)

Autophagy Inhibitor (LY294002) and 5-fluorouracil (5-FU) Combination-Based Nanoliposome for Enhanced Efficacy Against Esophageal Squamous Cell Carcinoma
por: Feng, Ye, et al.
Publicado: (2018)

Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer
por: Steber, Cole, et al.
Publicado: (2021)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

Spica Prunellae Extract Enhances Fluorouracil Sensitivity of 5-Fluorouracil-Resistant Human Colon Carcinoma HCT-8/5-FU Cells via TOP2α and miR-494
por: Fang, Yi, et al.
Publicado: (2019)

N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU
por: Zhang, Xiaofan, et al.
Publicado: (2009)

Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review
por: Yuwono, Kurniawan Agung, et al.
Publicado: (2023)

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
por: Dahan, Laetitia, et al.
Publicado: (2010)

Initial experience with topical fluorouracil (5-FU) for treatment of anal intraepithelial neoplasia (AIN) in HIV-positive patients
por: Snyder, Sean M, et al.
Publicado: (2010)

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
por: Bathe, Oliver F, et al.
Publicado: (2009)

Inhibition of G9a promoted 5-fluorouracil (5-FU) induced gastric cancer cell apoptosis via ROS/JNK signaling pathway in vitro and in vivo
por: Lou, Haizhou, et al.
Publicado: (2019)

Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU/HO-1 hybrid): design and preliminary in vitro evaluation
por: Salerno, Loredana, et al.
Publicado: (2021)

Herbal medicine Guan Chang Fu Fang enhances 5-fluorouracil cytotoxicity and affects drug-associated genes in human colorectal carcinoma cells
por: YU, CHEN, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a7tp5ge9qmjt1rf1mdroas9qb7